PILA PHARMA AB (PILA) AI Stock Analysis

PILA PHARMA AB

(Nasdaq OMX AB:PILA)

Select Model

Rating:44Neutral

Price Target:SEK 1.50▼(-3.85% Downside)

Action:reiterated

Date:09/24/26

Low score driven mainly by weak financial performance from revenue volatility, losses, and cash burn despite balance sheet strength, plus poor valuation on negative P/E. Neutral technicals offer minor support.

Positive Factors

Low Financial LeverageZero reported debt reduces near-term balance-sheet pressure and avoids interest obligations while the company advances its development program. This provides greater financial flexibility than a similarly loss-making biotech carrying substantial leverage, although it does not eliminate funding needs.

Negative Factors

Sharp Revenue ContractionThe steep TTM revenue decline shows that PILA has not established a stable or expanding commercial revenue base. Continued contraction from an already low level weakens operating leverage and leaves the company more dependent on successful clinical progress and future commercialization.

PILA PHARMA AB (PILA) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 71.26M
Dividend Yield: ―
Average Volume (3M): 80.89K
Price to Earnings (P/E): -3.8
Beta (1Y): 0.16
Revenue Growth: -71.19%
EPS Growth: -23.18%
Country: Sweden
Employees: 1
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

PILA PHARMA AB Business Overview & Revenue Model

Company Description

Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating...

How the Company Makes Money

As a clinical-stage pharmaceutical company, PILA PHARMA AB’s ability to generate recurring commercial revenue depends on successful drug development and subsequent commercialization or partnering. Specific, company-reported details on current revenue...

PILA PHARMA AB Financial Statement Overview

Summary

Weak income statement and cash flow due to revenue decline over 60%, negative margins, and heavy cash burn, partially offset by strong debt-free balance sheet with positive equity.

Income Statement

22Negative

Balance Sheet

88Very Positive

Cash Flow

18Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	275.74K	1.13M	775.00K	1.46M	1.88M	719.23K
Gross Profit	-5.95M	-6.82M	-8.12M	1.46M	1.88M	680.94K
EBITDA	-6.71M	-15.92M	-10.11M	-8.81M	-26.76M	-17.16M
Net Income	-16.77M	-16.86M	-11.24M	-9.93M	-26.78M	-17.21M
Balance Sheet
Total Assets	16.86M	16.22M	6.22M	8.46M	10.89M	31.81M
Cash, Cash Equivalents and Short-Term Investments	3.26M	15.90M	4.89M	5.95M	7.24M	28.21M
Total Debt	0	0	0	773.08K	0	0
Total Liabilities	748.00K	1.43M	963.00K	1.79M	1.36M	1.51M
Stockholders Equity	16.11M	14.78M	5.26M	6.66M	9.53M	30.30M
Cash Flow
Free Cash Flow	-20.79M	-9.19M	-7.82M	-4.85M	-9.09M	-9.36M
Operating Cash Flow	-20.79M	-9.19M	-7.82M	-4.85M	-9.09M	-9.36M
Investing Cash Flow	0	0	0	0	0	0
Financing Cash Flow	22.97M	20.19M	6.76M	3.56M	-11.88M	35.67M

PILA PHARMA AB Technical Analysis

Technical Analysis SentimentNeutral

Last Price1.56

Price Trends

50DMA1.71Negative

100DMA1.51Positive

200DMA1.51Positive

Market Momentum

MACD-0.05Positive

RSI46.48Neutral

STOCH76.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PILA, the sentiment is Neutral. The current price of 1.56 is below the 20-day moving average (MA) of 1.60, below the 50-day MA of 1.71, and above the 200-day MA of 1.51, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 46.48 is Neutral, neither overbought nor oversold. The STOCH value of 76.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:PILA.

PILA PHARMA AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:PILA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:PILA	44Neutral	SEK 71.26M	-3.84	-108.78%	―	-71.19%	-23.18%
SE:MODTX	41Neutral	SEK 31.19M	-1.02	-177.45%	―	―	0.22%
SE:ACE	39Underperform	SEK 77.45M	-1.20	-62.21%	―	―	58.15%
SE:ONCOZ	38Underperform	SEK 85.84M	-1.62	-2775.09%	―	115.26%	-230.43%

* Healthcare Sector Average

Performance Comparison

SE:PILA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:PILA	PILA PHARMA AB	1.56	-0.65	-29.41%
SE:ONCOZ	OncoZenge AB	3.11	-1.14	-26.75%
SE:ACE	Ascelia Pharma AB	0.58	-2.63	-81.93%
SE:MODTX	Modus Therapeutics Holding AB	0.18	-0.22	-54.68%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 24, 2026

PILA PHARMA AB AI Stock Analysis